Os negócios com o patrimônio genético da Islândia

Há quase um ano (17.02.2009) colocamos no blog o assunto do patrimônio genético da Islândia. "as ações da deCODE foram lançadas a US$ 30 e agora estão a cerca de US$ 0,45, a empresa, e principalmente o seu patrimônio, ou melhor o patrimônio genético islandês, pode ser colocado à venda em breve. É fácil constatar que o capital está bem protegido e que pode ser um bom investimento, basta não se preocupar com ética e outros pequenos detalhes..."

Em 6 de março, voltamos ao tema:

"Você que viu que o patrimônio genético da Islândia poderia ir a leilão e estava fazendo as contas da poupança para arrematá-lo, pode tirar o cavalinho da chuva. A deCOde parece que vai conseguir sobreviver aos tempos difíceis. Veja a notícia abaixo:

“Eight months after being targeted by California regulators with a ‘cease and desist’ letter, deCode Genetics, a biotech company based in Reykjavik, last week received the equivalent of the state’s blessing: a clinical laboratory licence.

deCode’s in-house laboratory has passed muster with state regulators, and the company can begin marketing genetic tests in California. Last June’s letter threatened deCode with penalties of up to US$10,000 a day for marketing to California residents (see Nature 453, 1148–1149; 2008).

Two other high-profile firms — 23andMe and Navigenics — that received the letter were granted licences in August.

Kári Stefánsson, deCode’s chief executive, says that the firm is awaiting a similar licence from the state of New York.” Nature fev.2009."

Hoje o The Great Beyond noticia:

"deCode makes a comeback - January 24, 2010

Two months after filing for bankruptcy, a subsidiary of the 14-year-old genomics company deCode, based in Reykjavik, Iceland, will be resurrected as a privately owned company.

The struggling company, which had made a name for itself with its genetic database of 140,000 Icelanders, was wracked with hundreds of millions of dollars in debt at the start of the financial crisis in the fall of 2007. In 2008, it was threatened with delisting from the NASDAQ stock exchange after its stocks dropped by 54%. DeCode challenged the delisting, but was forced to declare bankruptcy in November 2009.

Research at the new deCode will be headed by its founder, neuroscientist Kari Stefánsson, and the company will continue to develop gene-based diagnostics, perform personal genome scans, and contract with pharmaceutical firms, while abandoning its in-house drug discovery efforts. The rebirth was orchestrated by the venture capital consortium Saga Investments, which purchased the deCode subsidiary, Islensk Erfdagreining, with the approval of a Delaware bankruptcy court."